First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have increased from $2.09 to $2.38. The consensus estimate for 2025 earnings has improved from $4.33 to $7.31. Year to date, shares of ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...

The emergence of sophisticated AI methodologies capable of identifying individuals through intricate behavioral patterns amplifies these concerns and underscores the pressing need for robust privacy ...

CHELMSFORD, MA / ACCESSWIRE / September 16, 2024 / Harte Hanks, Inc. (NASDAQ:HHS), a global leader in customer experience for over 100 years, today announced a leadership transition within its sales ...